Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volagidemab in Type 1 Diabetes
NCT03117998Phase 2Completed
- Sponsor
- REMD Biotherapeutics, Inc.
- Start
- Sep 2017
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of volagidemab in type 1 diabetes mellitus (T1D) (3 arms), sponsored by REMD Biotherapeutics, Inc. Primary endpoint: Change in Average Daily Total Insulin Use at 12 weeks. Started Sep 2017; status: completed.
02
Drugs
volagidemab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03117998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03117998.